Takeda Pharmaceutical Files June 2025 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jun 6, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jun 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
TL;DR
Takeda filed its monthly 6-K report with the SEC on June 6, 2025.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on June 6, 2025, reporting as a foreign private issuer. The filing indicates Takeda is submitting its report for the month of June 2025 and will file its annual reports under Form 20-F.
Why It Matters
This filing is a routine update for Takeda as a foreign private issuer, providing standard disclosure to the SEC for the month of June 2025.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new material financial or operational information.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
- 0001395064-25-000076 (accession_number) — Unique identifier for the filing
- 001-38757 (sec_file_number) — SEC file number for Takeda
- 20250606 (date) — Filing date and period of report
FAQ
What type of filing is this for Takeda Pharmaceutical Company Limited?
This is a Form 6-K, a Report of Foreign Private Issuer.
When was this Form 6-K filed?
The filing was made on June 6, 2025.
What period does this report cover?
The report is for the month of June 2025.
Under which form does Takeda file its annual reports?
Takeda files its annual reports under Form 20-F.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 6, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).